32 - Instant insights: Blood-based biomarkers for Alzheimer’s Disease (8 min)

Approximately 55 million people have dementia. Alzheimer’s disease (AD) is the most common form of dementia, impacting nearly 7 million Americans. Blood-based biomarkers such as the beta amyloid 42/40 ratio and phosphorylated tau (p-tau217) are now providing earlier and more accessible insights into Alzheimer's pathology. These markers help differentiate Alzheimer's from other dementias, support early intervention, and improve diagnostic confidence. The Quest Diagnostics panel combines these biomarkers to generate a highly accurate likelihood score for Alzheimer's pathology, enhancing clinical decision-making and care planning. This episode will Describe the pathology of AD (2:00) Summarize the role of blood-based biomarkers in the evaluation of suspected AD (3:00) Explain how biomarkers can support patient evaluation and help clinical decision-making (6:30) To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions. Date: March 2026 Speaker(s):  Maeson Latsko, PhD Contributor(s): Maeson Latsko, PhD; Trisha Winchester, PhD; Amanda Backner; Kenneth French; Michael Prouse, PhD; Mouris Saghir, PhD; Matthew Stroh, PhD; Michael Racke, MD   Additional Resources Quest Diagnostics Clinical Education Center [Link] Test Summary: AD Detect FAQ: AD Detect Ordering information: AD-Detect™ ABeta 42/40 and p-tau217 Evaluation, Plasma   References:     Alzheimer's Association. Alzheimer’s Disease Facts and Figures. Alzheimer’s Disease and Dementia. Published 2025. https://www.alz.org/alzheimers-dementia/facts-figures ‌World Health Organization. Dementia. World Health Organization. Published March 31, 2025. https://www.who.int/news-room/fact-sheets/detail/dementia Palmqvist S, Whitson HE, Allen LA, et al. Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings. Alzheimers Dement. 2025;21(7):e70535. doi:10.1002/alz.70535